Introduction
============

Non-Hodgkin lymphoma (NHL) is a heterogeneous group of lymphoid malignancies and is the fourth most common malignancy in children and adolescents. Pediatric NHLs are known to have different distributions of pathologic subtypes and clinical features compared to adult NHLs. Most pediatric patients with NHL present diffuse high-grade lymphomas with frequent extranodal involvement \[[@b1-crt-2019-219],[@b2-crt-2019-219]\]. Treatment outcomes of pediatric NHL have been improved with effective treatment strategies according to different pathologic subtypes, and the current overall survival (OS) rate exceeds 80% \[[@b3-crt-2019-219]\]. However, most of these findings on pediatric NHLs are derived from studies in Western countries. Multicenter investigations on Asian patients with pediatric NHL are lacking except for a few nationwide studies in Japan, China, and South Korea \[[@b4-crt-2019-219]-[@b6-crt-2019-219]\]. This might be attributed to the heterogeneity and the low incidence of pediatric NHL, which prevents large-scale clinical studies. Therefore, in this study we analyzed the demographic and clinical features of a large number of pediatric patients with NHL in Asian countries and compared them with those of previous reports on patients in Western countries to provide a basis for further clinical investigation.

Materials and Methods
=====================

The medical records of 769 pediatric patients with NHL, who were diagnosed and treated in four participating institutions of Beijing, Shanghai, Nagoya, and Seoul, and in centers in Taiwan between January 2008 and December 2013, were reviewed retrospectively. Participating centers were the Asan Medical Center Children's Hospital (AMCCH) in Korea, Nagoya University Hospital (NUH) in Japan, Beijing Children's Hospital (BCH) and Shanghai Children's Medical Center in China, and Taiwan Pediatric Oncology Group centers. Demographic, clinical features, and survival outcomes were investigated.

NHL was diagnosed and classified according to the World Health Organization Classification of Hematological Malignancies \[[@b7-crt-2019-219]\]. Central review of the diagnosis was not performed. The St. Jude staging system was used for staging at diagnosis \[[@b8-crt-2019-219]\]. Staging analysis included physical examination, peripheral blood smear, and bone marrow (BM) aspiration and biopsy, cerebrospinal fluid (CSF) analysis, computed tomography (CT) and/or magnetic resonance imaging (MRI), fluorodeoxyglucose positron emission tomography and serum lactate dehydrogenase (LDH) concentration. Initial central nervous system (CNS) disease was diagnosed if one of the following was present: lymphoma cells in the CSF (\> 5 cells/μL CSF in patients with lymphoblastic lymphoma \[LL\]), cerebral infiltrates on cranial CT or MRI, or cranial nerve palsy not caused by an extradural mass. Patients with blasts of ≥ 25% in BM were diagnosed with acute lymphoblastic lymphoma and were not included in this study. However, exclusively in patients with Burkitt lymphoma (BL), those with BM involvement were included as stage IV regardless of the percentage of blasts in the BM.

Patients were treated with multi-agent chemotherapy regimens according to participating institutions. Most of the regimens adopted the backbone of NHL-Berlin-Frankfurt-Munster (BFM) or Children's Oncology Group (COG) protocols, which were stratified to the three main subgroups of LL, mature B-cell lymphoma, and anaplastic large cell lymphoma (ALCL).

Analysis of the probability of OS and event-free survival (EFS) was performed using the Kaplan-Meier method with differences compared by the log-rank test. The EFS was calculated from the date of diagnosis to the first event (first relapse, progression, secondary malignancy, or death from any cause) or the date of last follow-up. Cumulative incidence (CI) functions for competing events were constructed by the method of Kalbfleisch and Prentice and were compared with Gray's test. CIs of relapse were estimated considering death without relapse and secondary malignancies as competing events. Differences in the distributions of different parameters were examined using the chi-square or Fisher exact test. Statistical analysis was conducted using SPSS software ver. 23.0 (IBM Corp., Armonk, NY) and R ver. 3.1.1 (R Foundation for Statistical Computing, Vienna, Austria). p-values \< 0.05 were considered statistically significant.

1. Ethical statement
--------------------

This study was approved by the Institutional Review Board (IRB) of the Asan Medical Center Children's Hospital (No. 2020-0284). Due to retrospective nature of this study, informed consent was waived by IRB. This study was performed in accordance with the recommendations of the Declaration of Helsinki for biomedical research involving human subjects.

Results
=======

A total of 769 patients were enrolled in this study. Of them, 20 cases were excluded due to inadequate data. Patient characteristics are summarized in [Table 1](#t1-crt-2019-219){ref-type="table"}. Patients showed male predominance (male vs. female, 71% vs. 29%). The most common pathologic subtype was BL (36%) followed by LL (30%), ALCL (14%), and diffuse large B-cell lymphoma (DLBCL) (13%). Other rare lymphomas (2%) included seven other unspecified B-NHLs, five follicular lymphomas, three mucosa-associated lymphoid tissue lymphomas, two hydrovacciniforme-like lymphomas, and one plasmablastic lymphoma. There were slight differences in the pathologic subtype distributions according to the participating institutions and age. LL was more common in BCH, BL was more frequently observed in NUH, peripheral T-cell lymphoma (PTCL) was more often observed in AMCCH, and DLBCL was more common in Taiwan. In the analysis according to age, BL was predominant among patients under 14 years old while DLBCL was predominant among those aged 15-20 years ([Fig. 1](#f1-crt-2019-219){ref-type="fig"}). Most patients (81%) had advanced disease (≥ stage III) at diagnosis. CNS involvement and BM involvement were observed in 63 (8%) and 217 (29%) patients, respectively. Anaplastic lymphoma kinase (ALK) status was available in 51 patients among 107 patients with ALCL status, and 40 patients (78%) of them showed ALK positivity. The differences in the patterns of BM involvement and disease extent at diagnosis, according to pathologic subtype, are shown in [Table 2](#t2-crt-2019-219){ref-type="table"}. BM involvement was more frequently observed in LL (48%) than in other subtypes, and patients with BL (83%), LL (93%), and ALCL (79%) were more frequently diagnosed with advanced diseases (p \< 0.001). CNS involvement was more frequently observed in patients with BL (12%). However, the differences were not statistically significant (p \> 0.05). Median age at diagnosis was 8 years (range, 1 to 19). Median LDH level at diagnosis was 500 IU/mL (range, 100 to 17,333). The pathologic subtypes included 268 BLs, 224 LLs, 97 DLBCLs, 107 ALCLs, 35 PTCLs, and 18 other rare lymphomas (others).

Of the 749 patients, 84 (11%) died. During the 50.5 months of median follow-up duration, the 5-year OS, EFS, and CI of relapse were 89%, 84%, and 13%,respectively ([Fig. 2A](#f2-crt-2019-219){ref-type="fig"}). There were no significant differences in OS and EFS between institutions.

Univariate analysis of putative prognostic factors revealed that pathologic subtype, CNS involvement, stage, and initial LDH level were associated with prognosis ([Table 3](#t3-crt-2019-219){ref-type="table"}). Patients with PTCL showed significantly poorer prognosis, with 5-year EFS of 56%, compared with those with other subtypes (p \< 0.05). CNS involvement at diagnosis was associated with poor survival outcome, while BM involvement was not. Patients with CNS involvement at diagnosis had lower 5-year OS and EFS than patients without CNS involvement (p \< 0.05). Patients with early-stage NHL or those with LDH level below 250 IU/mL at diagnosis had excellent outcomes, with 5-year EFS of over 90%, compared to patients with advanced stage or high level of LDH (p \< 0.05).

Ninety-one of the 749 patients (12%) experienced disease relapse. Median time to relapse from diagnosis was 8 months (range, 0 to 41 months). Along with the factors affecting prognosis, pathologic subtype, CNS involvement and stage were the factors affecting relapse. Patients with ALCL and PTCL experienced relapse more frequently than patients with other subtypes, and patients with CNS involvement and advanced stage also experienced relapses more frequently ([Table 4](#t4-crt-2019-219){ref-type="table"}).

Of the 91 patients who experienced relapse, 57 (63%) died, including the 16 patients who received no treatment after relapse. In the analysis of putative prognostic factors, relapse within 12 months from diagnosis, subtype of BL and LL, and salvage regimen without autologous hematopoietic stem cell transplantation (HSCT) were associated with poor outcomes in patients with relapse ([Table 5](#t5-crt-2019-219){ref-type="table"}). ALCL and PTCL showed a higher incidence of relapse (CI of relapse in ALCL and PTCL, 26%; CI of relapse in BL, LL, and DLBCL: 11%, 10%, and 7%, respectively), but these relapsed cases were salvaged successfully, while relapsed BL and LL showed more dismal outcomes with 5-year OS of 14% and 17%,respectively ([Fig. 3](#f3-crt-2019-219){ref-type="fig"}). Regarding the salvage regimen, patients who received autologous HSCT had a successful outcome with 5-year OS of 77%.

Discussion
==========

Through this multicenter study, we found that the demographic features and clinical characteristics of pediatric NHL in the East Asia were similar to those of Western countries. However, some distinct aspects were observed.

BL and LL were the most frequent pathologic subtypes followed by DLBCL or ALCL. A previous study analyzed 2,084 patients with pediatric NHL in Western countries and reported that the incidence of BL, LL, ALCL, DLBCL, and primary mediastinal large B-cell lymphoma were 48%, 21%, 10%, 8%, and 2%, respectively \[[@b9-crt-2019-219]\]. The pathologic subtype distribution showed different patterns according to the age of patients in western study: BL, LL, and ALCL were more commonly found in children aged under 15 years, while DLBCL, LL, and BL were more frequently found in patients aged 15 years and over \[[@b10-crt-2019-219]\]. Our study showed similar patterns of pathologic subtype distribution according to patient age as previous studies. In addition, rare pathologic subtypes of lymphoma accounted for 10% of cases in the 15-19-year-old age group compared to 3% in the 0-14-year-old age group. PTCL is a pathologic subtype of pediatric NHL, and a BFM study group reported that 38 of 4,083 pediatric patients (0.9%) with NHL were diagnosed with PTCL \[[@b11-crt-2019-219]\]. In our study, PTCL was more frequently found, in 35 (5%) of 749 patients. Earlier studies showed that in Asia, Epstein-Barr virus (EBV)-associated natural killer (NK)/T-cell lymphomas were more prevalent in adults than they were in Western countries \[[@b12-crt-2019-219],[@b13-crt-2019-219]\]. However, there was no significant difference in the distribution of PTCL subtypes in children between the study of the BFM group and our study. In the BFM study, nine of the 38 patients (24%) with PTCL were reported to have NK/T-cell lymphomas, compared to 10 of the 35 patients (29%) with PTCL in our study. Thus, unlike previous studies on adult NHL, our study found no difference in the rate of NK/T-cell lymphoma. However, we cannot conclude that there are no ethnic or geographic differences in the biology of PTCL in children. Accordingly, further evaluation related to EBV infection is needed.

The clinical characteristics of pediatric NHL in our study were also similar to those of Western countries. The BFM group study on 2,084 pediatric patients with NHL reported a male to female ratio of 2.7:1 \[[@b9-crt-2019-219]\], similar to the value in our study (2.4:1). Seventy percent of pediatric patients with NHL were diagnosed with advanced diseases (≥ stage III) in the BFM study, compared to 81% in our study. While most patients were diagnosed with advanced diseases, BM involvement and CNS involvement were rarely observed. The BFM study observed 5% CNS involvement and 19% BM involvement, compared to 8% and 29%, respectively, in our study. Of note, BM and CNS involvement were more frequently observed in patients with BL and LL than in other subtypes.

Major advances in the treatment of pediatric NHL have been achieved over the last three decades. The current 3- or 5-year EFSs have been reported as approximately 70% to 90% in mature B-cell lymphomas, 75% to 85% in LLs, and 65% to 75% in ALCLs \[[@b1-crt-2019-219]-[@b3-crt-2019-219],[@b14-crt-2019-219]-[@b18-crt-2019-219]\]. The development of efficacious treatment strategies for different pathologic subtypes might have resulted in the improved treatment outcomes of pediatric NHL. Our study found that contemporary treatment strategies were successful for treating pediatric patients with NHL in East Asian countries. The treatment outcomes of 749 patients enrolled in our study were comparable with those of Western countries: the 5-year OS and EFS were 89% and 84%, respectively. Even though treatment protocols differed between institutions, most of the protocols used were based on the backbone of the NHL-BFM or COG protocols. Patients were mostly treated with established protocols stratified to the three main subgroups: LL, mature B-cell lymphoma and ALCL. Therefore, the treatment strategies of each participating institutions were similar to each other. Of note, the treatment outcomes of each institution were not significantly different.

The analysis of prognostic factors in pediatric NHL has been mainly performed for each pathologic subtype in precedent studies. In mature B-cell NHL, advanced stage (≥ stage III), increased LDH at diagnosis, adolescent age, and CNS involvement have been observed as poor prognostic factors \[[@b19-crt-2019-219],[@b20-crt-2019-219]\]. A recent BFM study on prognostic factors of mature B-cell NHL showed that presence of mediastinal involvement at the primary site was also a poor prognostic factor, while adolescent age was not associated with prognosis \[[@b21-crt-2019-219]\]. The COG group also found that disseminated disease, including BM and CNS, and a high LDH level were poor prognostic factors in mature B-cell NHL \[[@b22-crt-2019-219]-[@b24-crt-2019-219]\]. In LL, stage at diagnosis was the only identified risk factor, because the study of prognostic factors has been impeded by the rarity of the disease and by difficulties in obtaining appropriate material for immunophenotypic and molecular characterization \[[@b3-crt-2019-219],[@b14-crt-2019-219]\]. In ALCL, mediastinal involvement, visceral involvement, or skin lesions were indicated as poor prognostic factors in the study of the European Intergroup for Childhood Non-Hodgkin Lymphoma \[[@b3-crt-2019-219],[@b25-crt-2019-219]\]. Our study showed similar results: subtype of PTCL, CNS involvement, advanced stage, and high initial LDH level were associated with poor outcomes, whereas age, sex, and BM involvement were not associated with outcomes. A BFM study on pediatric NHL showed that age and sex had different effects on treatment outcomes and had different distributions according to the pathologic subtype \[[@b9-crt-2019-219]\]. As such, it may be more reasonable to perform analyses of prognostic factors independently for each subtype.

The outcomes of patients with relapse were dismal. The BFM group reported that 10% of 324 pediatric patients with LL experienced progression or relapse despite conventional frontline treatment, and the salvage rate was poor with an OS of 14% \[[@b26-crt-2019-219]\]. A Korean group study reported an OS of 32% in refractory or relapsed BL and mature B-ALL \[[@b27-crt-2019-219]\]. Similar results were noted in our study, showing a 5-year OS of 33% in relapsed cases. Of note, pathologic subtypes influenced the outcomes. Patients with BL and LL who had refractory or relapsed diseases had a higher rate of treatment failure with conventional salvage therapy than other subtypes: The 5-year OSs of relapsed BL and LL were 14% and 17%, respectively, while those of other subtypes were over 50%. These results show that conventional salvage regimens were not efficacious enough in most patients with relapsed BL and LL. Therefore, it is necessary to develop clinical studies to develop new salvage therapy for pediatric patients with relapsed NHLs, especially for BL and LL. Recent multicenter clinical trials of therapies for adult patients with refractory NHL and leukemia showed that blinatumomab and chimeric antigen receptor T-cell therapy could be efficacious salvage therapies \[[@b28-crt-2019-219]-[@b30-crt-2019-219]\]. This is a possible candidate for salvage therapy in pediatric patients with relapsed and refractory NHL.

As this is a case report form-based retrospective study that recruited a large number of cases from different countries, central review of pathological diagnosis was not possible, and the chemotherapy regimens used in each institution were not uniform. Even with these limitations, our study is noteworthy as the first report to reveal the demographic and clinical features of pediatric patients with NHL in East Asia. The results of this study could be a platform for future collaborative multinational studies in East Asia.
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![Pathologic subtype distribution according to age. BL was the most common subtype in patients under 14 years old (A), while DLBCL was in patients aged 15-20 years old (B). BL, Burkitt lymphoma; LL, lymphoblastic lymphoma; DLBCL, diffuse large B-cell lymphoma; ALCL, anaplastic large cell lymphoma; PTCL, peripheral T-cell lymphoma.](crt-2019-219f1){#f1-crt-2019-219}

![Treatment outcomes of the 749 pediatric patients with NHL (A) and treatment outcomes according to pathologic subtypes (B). OS, overall survival; EFS, event-free survival; CI, confidence interval; BL, Burkitt lymphoma; LL, lymphoblastic lymphoma; DLBCL, diffuse large B-cell lymphoma; ALCL, anaplastic large cell lymphoma; PTCL, peripheral T-cell lymphoma.](crt-2019-219f2){#f2-crt-2019-219}

![Treatment outcomes of patients with relapse according to subtype. Cumulative incidence of relapse (A) and overall survival (B) showed that, anaplastic large cell lymphoma (ALCL) and peripheral T-cell lymphoma (PTCL) had a higher incidence of relapse, but they were salvaged successfully compared to Burkitt lymphoma (BL) and lymphoblastic lymphoma (LL). DLBCL, diffuse large B-cell lymphoma.](crt-2019-219f3){#f3-crt-2019-219}

###### 

Patients' characteristics

  Characteristic                                           No. (%) (n=749)
  -------------------------------------------------------- -----------------
  **Age at diagnosis, median (range, yr)**                 7.5 (0.6-18.6)
  **Sex**                                                  
   Male                                                    530 (71.0)
   Female                                                  219 (29.0)
  **Pathologic subtype**                                   
   BL^[a)](#tfn1-crt-2019-219){ref-type="table-fn"}^       268 (35.7)
   LL                                                      224 (29.9)
   DLBCL                                                   97 (12.9)
   ALCL                                                    107 (14.3)
   PTCL^[b)](#tfn2-crt-2019-219){ref-type="table-fn"}^     35 (4.6)
   Others^[c)](#tfn3-crt-2019-219){ref-type="table-fn"}^   18 (2.4)
  **LDH level at diagnosis, median (range, IU/mL)**        500 (100-9,587)
  **BM involvement (of the evaluable 748 patients)**       
   Yes                                                     217 (29.0)
   No                                                      531 (70.8)
  **CNS involvement**                                      
   Yes                                                     63 (8.4)
   No                                                      686 (91.6)
  **St. Jude stage**                                       
   Ⅰ                                                       28 (3.7)
   Ⅱ                                                       113 (15.1)
   Ⅲ                                                       368 (49.1)

BL, Burkitt lymphoma; LL, lymphoblastic lymphoma; DLBCL, diffuse large B-cell lymphoma; ALCL, anaplastic large cell lymphoma; PTCL, peripheral T-cell lymphoma; LDH, lactate dehydrogenase; BM, bone marrow; CNS, central nervous system.

Burkitt leukemia was included in BL,

PTCL-not otherwise specified, natural killer/T-cell lymphoma and subcutaneous panniculitis T-cell lymphoma were included in PTCL,

Others: mucosa-associated lymphoid tissue lymphoma, other unspecified B-NHL, follicular lymphoma, hydrovascciniforme-like lymphoma, plasmablastic lymphoma.

###### 

BM, CNS involvement and disease extent at diagnosis according to pathologic subtype

                                     BL (n=268)   LL^[a)](#tfn4-crt-2019-219){ref-type="table-fn"}^ (n=224)   ALCL (n=107)   DLBCL (n=97)   PTCL (n=35)   Others (n=18)   Total (n=749)   p-value
  ---------------------------------- ------------ ----------------------------------------------------------- -------------- -------------- ------------- --------------- --------------- ----------
  **BM involvement**                                                                                                                                                                      
   Yes                               81 (30.2)    108 (48.2)                                                  12 (11.2)      9 (9.3)        2 (5.7)       5 (27.7)        217 (28.9)      \< 0.001
   No                                187 (69.8)   115 (51.3)                                                  95 (88.8)      88 (90.7)      33 (94.2)     13 (72.2)       531 (70.9)      
  **CNS involvement**                                                                                                                                                                     
   Yes                               32 (11.9)    17 (7.6)                                                    5 (4.7)        8 (8.2)        1 (2.8)       0               63 (8.4)        0.087
   No                                236 (88.1)   207 (92.4)                                                  102 (95.3)     89 (91.8)      34 (97.1)     18 (100)        686 (91.5)      
  **Advanced disease (stage ≥ 3)**                                                                                                                                                        
   Yes                               222 (82.8)   209 (93.3)                                                  85 (79.4)      66 (68.0)      18 (51.4)     10 (55.5)       610 (81.4)      \< 0.001
   No                                46 (17.2)    15 (6.7)                                                    22 (20.6)      31 (32.0)      17 (48.5)     8 (44.4)        139 (18.5)      

Values are presented as number (%). BM, bone marrow; CNS, central nervous system; BL, Burkitt lymphoma; LL, lymphoblastic lymphoma; ALCL, anaplastic large cell lymphoma; DLBCL, diffuse large B-cell lymphoma; PTCL, peripheral T-cell lymphoma.

One patient with LL did not have data of initial BM.

###### 

Univariate analysis of putative prognostic factors

  Factor                      No.   5-Year OS (%)   p-value    5-Year EFS (%)   p-value
  --------------------------- ----- --------------- ---------- ---------------- ----------
  **Sex**                                                                       
   Male                       530   89              0.678      84               0.651
   Female                     219   88                         83               
  **Age at diagnosis (yr)**                                                     
   ≤ 14                       681   88              0.383      84               0.289
   \> 14                      68    92                         80               
  **Pathologic subtype**                                                        
   BL                         268   89              0.032      88               \< 0.001
   LL                         224   89                         88               
   DLBCL                      97    93                         89               
   ALCL                       107   84                         71               
   PTCL                       35    75                         56               
   Others                     18    88                         80               
  **BM involvement**                                                            
   Yes                        217   86              0.479      81               0.482
   No                         531   89                         85               
  **CNS involvement**                                                           
   Yes                        63    76              0.003      74               0.019
   No                         686   89                         85               
  **St. Jude stage**                                                            
   Ⅰ-Ⅱ                        141   98              \< 0.001   94               \< 0.001
   Ⅲ-Ⅳ                        608   86                         82               
  **Initial LDH (IU/mL)**                                                       
   ≤ 250                      170   96              \< 0.001   93               \< 0.001
   \> 250                     579   86                         81               

OS, overall survival; EFS, event-free survival; BL, Burkitt lymphoma; LL, lymphoblastic lymphoma; DLBCL, diffuse large B-cell lymphoma; ALCL, anaplastic large cell lymphoma; PTCL, peripheral T-cell lymphoma; BM, bone marrow; CNS, central nervous system; LDH, lactate dehydrogenase.

###### 

Characteristics of relapsed pediatric NHL

  Characteristic                            No. (n=749)   Non-relapse group (n=658)   Relapse group (n=91)   p-value
  ----------------------------------------- ------------- --------------------------- ---------------------- ---------
  **Time from diagnosis to relapse (mo)**                                             7.8 (0-41.2)           
  **Age at diagnosis (yr)**                               7 (1-18)                    8.2 (0.6-16.4)         0.446
  **Sex (%)**                                                                                                
   Male                                     530           467 (71.0)                  63 (69.2)              0.732
   Female                                   219           191 (29.0)                  28 (30.8)              
  **Pathologic subtype**                                                                                     
   BL                                       268           239 (36.3)                  29 (31.9)              0.001
   LL                                       224           203 (30.9)                  21 (23.1)              
   DLBCL                                    97            90 (13.7)                   7 (7.7)                
   ALCL                                     107           81 (12.3)                   26 (28.6)              
   PTCL                                     35            29 (4.4)                    6 (6.6)                
   Others                                   18            16 (2.4)                    2 (2.1)                
  **LDH at diagnosis (IU/mL)**                            476 (100-9,587)             610 (113-17,333)       0.014
  **BM involvement**                                                                                         
   Yes                                      217           183 (27.8)                  35 (38.4)              0.098
   No                                       531           475 (72.2)                  58 (63.7)              
  **CNS involvement**                                                                                        
   Yes                                      63            50 (7.5)                    13 (14.2)              0.031
   No                                       686           608 (92.4)                  78 (85.7)              
  **St. Jude stage**                                                                                         
   Ⅰ                                        28            26 (4.0)                    2 (2.2)                0.005
   Ⅱ                                        113           108 (16.4)                  5 (5.5)                
   Ⅲ                                        368           326 (49.5)                  41 (45.1)              
   Ⅳ                                        240           197 (29.9)                  43 (47.2)              

Values are presented as median (range) or number (%). NHL, non-Hodgkin lymphoma; BL, Burkitt lymphoma; LL, lymphoblastic lymphoma; DLBCL, diffuse large B-cell lymphoma; ALCL, anaplastic large cell lymphoma; PTCL, peripheral T-cell lymphoma; LDH, lactate dehydrogenase; BM, bone marrow; CNS, central nervous system.

###### 

Univariate analysis of putative prognostic factors of relapsed pediatric NHL

  Factor                                           No. (n=91)   5-Year OS (%)   p-value
  ------------------------------------------------ ------------ --------------- ----------
  **Median time from diagnosis to relapse (mo)**                                
   ≤ 12                                            68           30              0.003
   \> 12                                           23           46              
  **Subtype**                                                                   
   BL                                              29           14              0.001
   LL                                              21           17              
   DLBCL                                           7            50              
   ALCL                                            26           51              
   PTCL                                            6            75              
   Others                                          2            67              
  **Salvage regimen**                                                           
   CTx only                                        55           36              \< 0.001
   CTx+Auto-HSCT                                   10           77              
   CTx+Allo-HSCT                                   10           33              

NHL, non-Hodgkin lymphoma; BL, Burkitt lymphoma; LL, lymphoblastic lymphoma; DLBCL, diffuse large B-cell lymphoma; ALCL, anaplastic large cell lymphoma; PTCL, peripheral T-cell lymphoma; CTx, chemotherapy; Auto-HSCT, autologous hematopoietic stem cell transplantation; allo-HSCT, allogeneic hematopoietic stem cell transplantation.

[^1]: Jin Kyung Suh and Yi-Jin Gao contributed equally to this work.
